Replimune Stock Options Expiring on 20th of December
| REPL Stock | USD 14.05 0.33 2.29% |
Replimune's latest option contracts expiring on 2024-12-20 are carrying combined implied volatility of 0.17 with a put-to-call open interest ratio of 0.0 over 14 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2024-12-20. The total put volume is at 382, with calls trading at the volume of 382. This yields a 1.09 put-to-call volume ratio.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Replimune Group In The Money Call Balance
When Replimune's strike price is surpassing the current stock price, the option contract against Replimune Group stock is said to be in the money. When it comes to buying Replimune's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Replimune Group are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Replimune Current Options Market Mood
Replimune's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Replimune Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Replimune's options investors are not very successful. Replimune's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Replimune contract
Base on the Rule 16, the options market is currently suggesting that Replimune Group will have an average daily up or down price movement of about 0.0106% per day over the life of the 2024-12-20 option contract. With Replimune trading at USD 14.05, that is roughly USD 0.001493. If you think that the market is fully incorporating Replimune's daily price movement you should consider buying Replimune Group options at the current volatility level of 0.17%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Replimune |
Replimune Option Chain
When Replimune's strike price is surpassing the current stock price, the option contract against Replimune Group stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Replimune's option chain is a display of a range of information that helps investors for ways to trade options on Replimune. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Replimune. It also shows strike prices and maturity days for a Replimune against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Expiration | Current Spread | Last Price | |||
Call | REPL Option Call 20-12-2024 7 | 0 | 2024-12-20 | 0.0 - 0.0 | 7.2 | In |
Call | REPL Option Call 20-12-2024 10 | 0 | 2024-12-20 | 0.0 - 0.0 | 6.9 | In |
Call | REPL Option Call 20-12-2024 12 | 0 | 2024-12-20 | 0.0 - 0.0 | 2.34 | In |
Call | REPL Option Call 20-12-2024 15 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.7 | |
Call | REPL Option Call 20-12-2024 17 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.15 | |
Call | REPL Option Call 20-12-2024 20 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.1 | |
Call | REPL Option Call 20-12-2024 22 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.1 | |
Put | REPL Option Put 20-12-2024 22 | 0 | 2024-12-20 | 0.0 - 0.0 | 9.0 | In |
Put | REPL Option Put 20-12-2024 20 | 0 | 2024-12-20 | 0.0 - 0.0 | 4.8 | In |
Put | REPL Option Put 20-12-2024 15 | 0 | 2024-12-20 | 0.0 - 0.0 | 1.3 | In |
Put | REPL Option Put 20-12-2024 12 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.35 | |
Put | REPL Option Put 20-12-2024 10 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.12 | |
Put | REPL Option Put 20-12-2024 7 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.05 | |
Put | REPL Option Put 20-12-2024 5 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.05 |
Replimune Market Cap Over Time
Market Cap |
| Timeline |
Replimune Total Stockholder Equity
Total Stockholder Equity |
|
Replimune Corporate Management
| Sushil Patel | Chief Officer | Profile | |
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Tanya MS | Chief Officer | Profile | |
| Pamela Esposito | Chief Business Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.